Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Challenging Case of Progressive Pachymeningitis
Infectious Disease
P13 - Poster Session 13 (5:30 PM-6:30 PM)
13-013

Describe a case of worsening pachymeningitis with an unusual etiology.

Pachymeningitis, thickening of dura mater and increased meningeal signal intensity, has a broad differential including infectious, autoimmune, inflammatory, and neoplastic etiologies.

77 year-old woman with a history of diabetes, bilateral malignant otitis externa (2015), and chronic headaches after head trauma (2018) underwent brain MRI demonstrating pachymeningitis in July 2018. On examination she was well-appearing with no new neurologic deficits. Outpatient evaluation including LP was unrevealing. In March 2019 MRI brain and orbits demonstrated progression of pachymeningitis into the orbital apex and a ring-enhancing lesion in the left frontal lobe for which she was admitted to the hospital. She reported sensitivity to light and worsening of left eye vision. Exam revealed new left disc pallor with rAPD, proptosis, ophthalmoparesis, and visual loss.

Broad infectious workup including repeat LP was unremarkable. Rheumatologic studies demonstrated elevated ESR and CRP, positive anti-SS-A and elevated IgG4 subclass. CT chest/abdomen/pelvis and CSF cytology/cytometry were negative. She underwent a dural-based biopsy which demonstrated hyphae consistent with a fungal organism and abundant IgG4-positive plasma cells. IgG4+ staining and elevated IgG4 levels were thought to be due to an immune response to a fungal infection as opposed to IgG4-related disease. The patient was started empirically on amphotericin and voriconazole. While the culture showed no growth, fungal PCR resulted as Aspergillus flavus. Repeat MRI showed improvement in pachymeningeal thickening and size of abscess.

There are only four case reports in the literature of Aspergillus flavus causing pachymeningitis. All four cases involved a history of either diabetes, otitis media, or both. In this case, dural biopsy elucidated the etiology and directed treatment. Clinicians should consider fungal etiology in patients with progressive pachymeningitis, especially in a patient with diabetes and history of otic disease.

Authors/Disclosures
Elizabeth Pedowitz, MD (Memorial Sloan Kettering Cancer Center)
PRESENTER
No disclosure on file
Fred D. Lublin, MD, FÂé¶¹´«Ã½Ó³»­ (Icahn School of Medicine At Mount Sinai) Dr. Lublin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche/Genentech. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medimmune/Viela Bio/Horizon. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Receptos/Celgene/BMS. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Labcorp. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuralight. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Entelexo. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Lublin has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avotres. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Lublin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Lublin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Lublin has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Multiple entities. Dr. Lublin has stock in Avotres. Dr. Lublin has stock in Neuralight. The institution of Dr. Lublin has received research support from Brainstorm. The institution of Dr. Lublin has received research support from biogen. The institution of Dr. Lublin has received research support from NIH.
Ilana B. Katz Sand, MD (Corinne Goldsmith Dickinson Center for MS) The institution of Dr. Katz Sand has received research support from National Multiple Sclerosis Society. The institution of Dr. Katz Sand has received research support from Hirschl Foundation. The institution of Dr. Katz Sand has received research support from National Institutes of Health. Dr. Katz Sand has received personal compensation in the range of $500-$4,999 for serving as a Conference presenter with Âé¶¹´«Ã½Ó³»­.